Status:

COMPLETED

A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients

Lead Sponsor:

Santhera Pharmaceuticals

Conditions:

Friedreich's Ataxia

Eligibility:

All Genders

8+ years

Phase:

PHASE3

Brief Summary

The purpose of this trial is to study the efficacy, safety and tolerability of idebenone in 12 months of treatment in children and adults with Friedreich's Ataxia. This is a randomised placebo-control...

Detailed Description

Idebenone, a short-chain analogue of Co-enzyme Q10 (CoQ10), has the potential to moderate underlying causes of Friedreich's Ataxia through its antioxidant activity and its role as an electron carrier ...

Eligibility Criteria

Inclusion

  • Documented diagnosis of FRDA with confirmed FRDA mutations
  • Patients 8 years of age or older at baseline
  • Patients with body weight ≥ 25kg
  • Patients who in the opinion of the investigator are able to comply with the requirements of the study, including swallowing the medication
  • Negative urine pregnancy test at screening and at baseline (women of childbearing potential)

Exclusion

  • Treatment with idebenone or Coenzyme Q10 within the past 1 month
  • Pregnancy and/or breast-feeding
  • Clinically significant abnormalities of clinical haematology or biochemistry including, but not limited to, elevations greater than 1.5 times the upper limit of normal of SGOT, SGPT, or creatinine
  • Past or present history of abuse of drugs or alcohol

Key Trial Info

Start Date :

April 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2010

Estimated Enrollment :

232 Patients enrolled

Trial Details

Trial ID

NCT00905268

Start Date

April 1 2006

End Date

January 1 2010

Last Update

June 27 2016

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Universitätsklinik Innsbruck

Innsbruck, Austria, 6020

2

Hôpital Erasme - Université Libre de Bruxelles

Brussels, Belgium, 1070

3

Hôpital de la Salpêtrière - INSERM U679, Neurologie et Thérapeutique expérimentale

Paris, France, 75651

4

HELIOS Klinikum BerlinBuch

Berlin, Germany, 13125